Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

NCT04174755 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide helps people with HIV and obesity lose weight.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 80 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2022-06 · est. completion 2027-07

Where 1 site · Ireland

What this study is testing ClinicalTrials.gov NCT04174755 ↗

Description as written by the study sponsor.

The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese PWH is still unexplored. The aim of this study is to assess the efficacy and safety of semaglutide in achieving greater weight loss compared to diet and excercise alone in obese PWH and to explore the effect of semaglutide on the immune function, markers of immune activation, viral reservoir, markers of glucose and lipid metabolism and gut microbiome.

Treatments tested

Semaglutide Injectable Product also known as Ozempic Drug

Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
Standard of care also known as Diet and exercise Behavioral

Diet and exercise advice for 40 weeks

Main thing measured	Changes in total body weight (in Kg)
Sponsor	University College Dublin
Conditions studied	Obesity, HIV-1-infection
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04174755 ↗